ADA Scientific Sessions 2025 Abstract · Jun 13, 2025

Sensitivity of Different Screening Approaches for Early Hyperglycemia in Pregnancy

By SIMMONS D, NOLAN CJ, IMMANUEL J et al.

Introduction and Objective: The 2025 ADA standards recognize early pregnancy dysglycemia is associated with worse outcomes, and recommend detection with either fasting glucose (FG) or A1C. This study compared different early glycemic screening strategies for overt diabetes (ODIP) and GDM prediction. Methods: Pregnant women with GDM risk factors enrolled in a multicenter early GDM RCT had a 75g OGTT and A1C <20 wks using ADA ODIP and GDM criteria. Repeat OGTT occurred at 24-28 wks if untreated (normal OGTT and randomized 50% early GDM). Area under the receiver operator curve (AUROC) with 95%CI was used for ODIP and late GDM prediction. The proportion of late OGTTs avoided included those with an A1C or FG <90% sensitivity thresholds or reaching the ADA early screening thresholds (A1C≥5.9%; FG≥110 mg/dL). Results: Among 3515 women, mean age was 31±5 yrs, BMI 29.9±7.4 kg/m2, OGTT gestation 16±3 wks, 40.6% were European. A1C and FG had similar AUROCs for ODIP and similar, but lower, AUROCs for GDM. The ADA-recommended A1C and FG thresholds were<50% sensitive for ODIP and <5% sensitive for GDM. An early FG threshold of 92 mg/dL was <70% sensitive for ODIP and persistent GDM. An early A1C threshold of 4.8% or FG of 76 mg/dL (@90% sensitivity for GDM) could avoid 22.7% of 24-28 week OGTTs (Table 1). Conclusion: The 2025 ADA recommended early pregnancy A1C and FG thresholds are insensitive tests for detecting women with ODIP and later pregnancy GDM. Disclosure: D. Simmons: Research Support; Novo Nordisk, AMSL. Other Relationship; Abbott, Abbott, Boehringer-Ingelheim. Speaker's Bureau; Ascensia Diabetes Care. C.J. Nolan: None. J. Immanuel: None. H. Teede: None. J.R. Flack: None. V.W.M. Wong: None. E. Hibbert: None. M. McLean: Advisory Panel; Recordati Rare Diseases. A. Kautzky-Willer: None. J. Harreiter: None. H.E. Backman: None. E.J. Gianatti: None. A. Sweeting: None. V. Mohan: Speaker's Bureau; Novo Nordisk. Advisory Panel; Abbott. Research Support; Servier Laboratories. Speaker's Bureau; USV Private Limited, Sanofi, Medtronic, Eli Lilly and Company. W. Hague: None. Funding: NHMRC (grants 1104231 and 2009326); Region ?rebro Research Committee Dnr OLL-970566, OLL-942177; Medical Scientific Fund of the Mayor of Vienna, project 15205; South Western Sydney Local Health District Academic Unit grant 2016; Western Sydney University Ainsworth Trust grant 2019

doi.org/10.2337/db25-178-orBiomarkers

AgingResearch.News